Inclusion criteria were adult patients with colorectal cancers and histology of adenocarcinoma. Patient's records were reviewed for age, gender, site of tumor, grade, histological subtype, staging according to TNM staging system 10 , date of recurrence or progression of the disease and date of death or last follow-up.
chemotherapy received:
According to disease stage and performance status of the patients, variable types of chemotherapy regimen were taken.
5-flourouracil and leucovorin:
• Leucovorin 200 mg/m 2 IV over 2 hours on days 1&2.
• Fluorouracil 400 mg/m 2 IV push on days 1&2.
• Fluorouracil 600 mg/m 2 /day IV continuous infusion over 22 hours on days 1&2.
capcitabine:
Capecitabine 1000 mg/m 2 oral twice daily on days 1 to 14 of a 3-week cycle.
FoLFoX:
• Oxaliplatin 85 mg/m 2 IV over 2 hours on Day 1.
• Leucovorin 200 mg/m
2 IV over 2 hours on days 1&2.
FoLFIrI:
• Irinotecan 180 mg/m 2 over 90 minutes on day 1.
Progression free survival (PFS) was calculated from the date of starting chemotherapy to date of the confirmation of disease progression or death or last follow-up. Disease free survival (DFS) was calculated from the date of surgery to the date of disease recurrence or death or last follow-up. Overall survival (OS) is defined as the time from date of surgery or pathological diagnosis until the date of death (from any cause) or the date of last follow-up.
statistical analysis:
Data was analyzed using SPSSwin statistical package version 17 (SPSS Inc., Chicago, IL). Numerical data were expressed as mean and standard deviation or median and range as appropriate. Qualitative data were expressed as frequency and percentage. Chi-square test (Fisher's exact test) was used to examine the relation between qualitative variables. A P-value ≤ 0.05 was considered statistically significant. Progression and survival times were estimated using the Kaplan-Meier method.
resuLts
This study includes 288 patients. Their age ranged between (16-80 years) with a median age of 48.0 years. In ( fig.1 ) the age distribution is demonstrated. Patients forty years or younger represent 34.7%, and those older than forty years represent 64.3%. Out of the 288 patients, 164 patients were male (56.9%) and 124 patients were female (43.1%).
Younger patients (≤40 years) had statistical significant correlation with tumor grade III (35%) versus (7.97%) for older patients (P= 0.05). The relationship between age groups and tumor stages was statistically significant as analysis for non-metastatic patients revealed that (≤40 years) had higher incidence of stage III (59%) than in the older age group which had higher incidence of Stage II (61%) (P= 0.04) as seen in Table (1). Regarding the histo-pathological examination, all specimens were invasive adeno-carcinoma. From all specimens 28.8% were mucinous type. Statistically analyzing data for colon and rectal cases versus various clinic-epidemiological aspects like age groups, gender, histopathology, grade, and stage of disease did not show any statistical significance of any over the other as seen in Table ( 2).
Patients with stage I disease (9 patients) received no treatment, just follow-up. For stage II disease (75 patients) fourteen patients were on follow-up, thirty two patients received 5-flourouracil and leucovorin regimen, five patients received capcitabine tablets and twenty four received FOLFOX regimen. For stage III disease (82 patients) seventy one patients received FOLFOX regimen and seven patients received 5-flourouracil and leucovorin regimen and four patients were on followup only. For stage IV disease (76 patients) forty three patients received FOLFOX regimen as a first-line treatment, twenty eight patients received FOLFIRI regimen and five patients received 5-flourouracil and leucovorin regimen.
For the purpose of prognosis of younger patients on different stage of CRC, patients were divided into two groups first one include early stage cases (stage I-III) and second group include metastatic cases (stage IV).
In the first group (stage I-III), we found 166 patients, 57 of them were 40 years or younger. 5-years DFS for (≤40 years) were 47% versus 60% for above 40 years patients (P= 0.069). 5-years OS for (≤40 years) were 50.87% versus 64% for older patients (P= 0.037). 
dIscussIon
A major concern needing to be addressed in CRC is the correlation of age with prognosis, especially that world wide data regarding this point is conflicting [7] [8] [9] . ** Egyptian CRC patients carries unique genetic features that differ from European and American races 11, 12 . Accordingly, this study was planned to evaluate the real incidence of younger patients and its impact with different epidemiological features on the prognosis in different stages of CRC.
Considering age distribution, 34.7 % of our patients were 40 years old or younger which coincides with the previous Egyptian studies, in which the incidence of CRC in patients 40 years old or younger ranged from 30% to 40%5-7 In contrast to western countries where the risk of CRC begins to increase after the age of 40 years and rises sharply at ages 50 to 55 years; the risk doubles with each succeeding decade, and continues to rise exponentially, 90% of these cancers occur in people older than 50 years of age & the incidence of colorectal cancer peaks at about age 65 years.3 Similarly in the United Kingdom, only 2 to 3 per cent of colon cancer occurs in patients younger than the age of 40 years 13 , the high prevalence of the Egyptian CRC in the young could not be explained by Lynch or other hereditary syndromes 12, 14, 15 , but could be explained by exposure to oncogenic agents at younger age, an explanation which needs more evaluation via environmental and genetic testing.
On the other hand, we noticed that younger patients have more advanced stages and poorer grades than older patients at presentation. This is similar to data of the study conducted by Minardi et al; where more aggressive tumor behavior and worse overall survival rate have been noted in patient with colon cancer, whose disease was diagnosed before the age of 40 years 16 other explanation for advanced stage at presentation could be that young patients with colorectal cancer may be diagnosed late due to low suspicion of malignancy in these patients.
Regarding gender, we found insignificant male predominance. Slightly more than half the cases were males (56.9%), giv ing a male: female ratio of 1.3:1 which is nearly similar to the results of previous Egyptian studies [5] [6] [7] . In our study, 28.8% of patients had mucinous adenocarcinoma, which were nearly similar to that reported by the study conducted by Soliman et al. study, where 30.6% of patients had mucinproducing tumors 5 .
In this study, we found that epidemiological features of patients with rectal carcinoma were similar to colonic carcinoma with regard to age, sex, histological types and TNM stages. This is similar to previous Egyptian studies with the exception of El-Bolkainy et al. data from the National Cancer Institute, Cairo University; where it was found that rectal carcinoma patients were younger than those with colonic carcinoma 17 .
Regarding the prognosis of younger patients in CRC, we reported a non-significant worse DFS and significant worse OS for stage I-III patients, in addition to significant worse PFS and OS for stage IV patients. This means that younger patients carry a bad prognosis relative to older patients. These results could be similar to the results of a large pooled Analysis over 6,284 patients from nine phase III trials of advanced colorectal Cancer. With only 188 of these patients (3% of total patients) were younger than 40 years old, and they found that younger patients had worse PFS but not OS 9 .
This difference between our data and world wide data can be explained mainly by different genetic features for Egyptian patients. Delayed presentation and also it can be due to less available effective treatment available than European or American hospitals. For stage I-III patients we reported non-significant worse DFS (P= 0.069) and significant worse OS (P= 0.037). It is worth mentioning that incidence of stage III in regard to stage I-II was significantly higher in younger patients than older ones, a finding that might explain the worse survival for younger patients in early disease.
concLusIon
In Egyptian CRC patients, higher percentage of younger patients was noticed. In stage I-III disease, patients ≤40 years carried a worse OS due to higher percentage of stage III disease; while in stage IV, patients ≤40 years carried a worse PFS and OS. Large national study to focus on different oncogenic agents that promote for higher incidence of CRC in younger patients will be satisfactory in the near future.
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